Search
Transient receptor potential cation channel subfamily A member 1
go.drugbank.com/bio_entities/BE0001122TargetHumansHas a central role in the pain response to endogenous inflammatory mediators, such as bradykinin and to a diverse array of irritants. … Has a relatively high Ca(2+) selectivity, with a preference for divalent over monovalent cations (Ca(2+) > Ba(2+) > Mg(2+) > NH4(+) > Li(+) > K(+)), the influx of cation into the cytoplasm leads to membrane
Polypeptides: Transient receptor potential cation channel subfamily A member 1Low affinity immunoglobulin gamma Fc region receptor III-A
go.drugbank.com/bio_entities/BE0002097TargetHumansOptimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-ASynonyms: IgG Fc receptor III-APanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: hydroxypropyl-B-cyclodextrin-panobinostat complex, (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamideBivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalBivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin.
Products: ANGIOMAX® POLVO LIOFILIZADO PARA RECONSTRUIR A SOLUCIÓN INYECTABLE (50MG/ML), OBIVADIN 250 MG IV ENJEKSIYON/INFÜZYON IÇIN LIYOFILIZE TOZ, 1 ADETVitespen
go.drugbank.com/drugs/DB06400InvestigationalSynonyms: Endoplasmin (human tumor rejection antigen 1), Heat shock protein-peptide complex-96 vaccineCategories: Complex MixturesSuccinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial
go.drugbank.com/bio_entities/BE0002256TargetEnzymeHumans) and produce a new acyl-CoA. … Catalyzes the first, rate-limiting step of ketone body utilization in extrahepatic tissues, by transferring coenzyme A (CoA) from a donor thiolester species (succinyl-CoA) to an acceptor carboxylate (acetoacetate
Polypeptides: Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrialNKG2-A/NKG2-B type II integral membrane protein
go.drugbank.com/bio_entities/BE0010560TargetHumansIn complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence … Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity (PubMed:12387742).
Polypeptides: NKG2-A/NKG2-B type II integral membrane proteinSynonyms: NK cell receptor A, NKG2-A/B-activating NK receptorHyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. … Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
Products: POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION PARA ADMINISTRACIÓN OFTALMICA, HYLASE® DESSAU 150 IUClostridium tetani toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10583ApprovedInvestigationalClostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. … It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus.
Mixtures: 3 ANTIGEN, Neisvac-CCategories: Complex MixturesDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. … Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsProducts: DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 mg/2ml, DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml